Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's Bracelet-1 was in HR+/HER2 negative breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 27, 2023 10:19am

147 Views

Post# 35467105

RE:ONCY's Bracelet-1 was in HR+/HER2 negative breast cancer

Should read: Tolaney SM et al. JAMA Oncol (2020) showed that the addition of an PD-1 immune checkpoint inhibitor (pembrolizumab) to chemotherapy (eribulin) for metastatic hormone receptor-positive breast cancer patients who pretreated with 0 to 2 lines of salvage chemotherapy did not improve ORR, PFS, or OS (immature) compared with chemotherapy (eribulin) alone.

<< Previous

Bullboard Posts

Next >>

FLYHT and WestJet partner on weather forecasting